From: Emerging role of 18F-FDG PET/CT in Castleman disease: a review
Major criteria  1. Lymph nodes with histopathologic features consistent with iMCD spectrum  2. Enlarged lymph nodes (≥ 1 cm in short-axis diameter) in ≥ 2 lymph node regions |
Minor criteria Laboratory  1. Elevated CRP or ESR  2. Anemia  3. Thrombocytopenia or thrombocytosis  4. Hypoalbuminemia  5. Renal dysfunction or proteinuria  6. Polyclonal hypergammaglobulinemia Clinical  1. B symptoms  2. Hepatomegaly or splenomegaly  3. Fluid accumulation  4. Eruptive cherry hemangiomatosis  5. Violaceous papules  6. Lymphocytic interstitial pneumonitis |
Supporting features  1. Elevated IL-6, VEGF, IgA, IgE, LDH, and/or B2M  2. Reticulin fibrosis of bone marrow  3. Disorders associated with iMCD: paraneoplastic pemphigus, bronchiolitis obliterans organizing pneumonia, autoimmune cytopenias, polyneuropathy, inflammatory myofibroblastic tumor |
Exclusion criteria  1. Infection: HHV-8, EBV, CMV, toxoplasmosis, HIV, active tuberculosis  2. Autoimmune/autoinflammatory: systemic lupus erythematosus, rheumatoid arthritis, adult-onset Still disease, juvenile idiopathic arthritis, autoimmune lymphoproliferative syndrome  3. Malignancy: lymphoma, multiple myeloma, POEMS syndrome, primary lymph node plasmacytoma, follicular dendritic cell sarcoma |